Rhenovia Pharma SAS has raised €540,000 in a Series B financing round from existing investors to support development of its technology for predicting the safety of new pharmaceutical compounds in patients with neurological diseases. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
